Hematotoxicity Correlation of MTHFR Gene Polymorphism with High-dose of Methotrexate in Hematological Neoplasm Patients ：A Meta-analysis

LIU Shuang; SONG Zaiwei; YI Zhanmiao; ZHAO Rongsheng

您当前的位置：

首页 >

文章列表页 >

Hematotoxicity Correlation of MTHFR Gene Polymorphism with High-dose of Methotrexate in Hematological Neoplasm Patients ：A Meta-analysis

更新时间：2022-06-21

- Hematotoxicity Correlation of MTHFR Gene Polymorphism with High-dose of Methotrexate in Hematological Neoplasm Patients ：A Meta-analysis
- China Pharmacy Vol. 31, Issue 7, (2020)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2020，
扫描看全文
LIU Shuang, SONG Zaiwei, YI Zhanmiao, et al. Hematotoxicity Correlation of MTHFR Gene Polymorphism with High-dose of Methotrexate in Hematological Neoplasm Patients ：A Meta-analysis. [J]. China Pharmacy 31(7).(2020)
DOI：

LIU Shuang, SONG Zaiwei, YI Zhanmiao, et al. Hematotoxicity Correlation of MTHFR Gene Polymorphism with High-dose of Methotrexate in Hematological Neoplasm Patients ：A Meta-analysis. [J]. China Pharmacy 31(7).(2020) DOI：

摘要

目的：系统评价血液恶性肿瘤患者中亚甲基四氢叶酸还原酶（MTHFR）C677T及A1298C多态性与大剂量甲氨蝶呤（HD-MTX）血液系统不良事件的相关性。方法：系统检索Medline、Embase、ClinicalTrials.gov、中国学术期刊网络出版总库、万方数据库、中国生物医学文献数据库，收集采用HDMTX治疗血液恶性肿瘤涉及MTHFRC677T及A1298C基因多态性的队列研究，时限均为自建库起至2018年3月。对符合纳入标准的文献进行资料提取，并采用纽卡斯尔-渥太华量表进行质量评价后，应用RevMan5.3软件对不同遗传模型下HDMTX血液系统不良事件进行Meta分析。结果：共纳入25项队列研究，其中23项研究关注MTHFRC677T位点（1858例患者）、16项研究关注MTHFRA1298C位点（1088例患者）。Meta分析结果表明，MTHFRC677T突变型显著增加了血液毒性[TT/CTvs.CC：OR＝1.57，95％CI（1.12，2.20），P＝0.009；TTvs.CT/CC：OR＝2.19，95％CI（1.49，3.23），P＜0.001；Tvs.C：OR＝1.34，95％CI（1.03，1.74），P＝0.03]、严重血液毒性[TT/CTvs.CC：OR＝2.33，95％CI（1.43，3.81），P＜0.001]的发生风险，具体包括增加了白细胞减少[TT/CTvs.CC：OR＝1.37，95％CI（1.02，1.82），P＝0.03]、严重白细胞减少[TT/CTvs.CC：OR＝1.63，95％CI（1.03，2.56），P＝0.04]、严重粒细胞减少[TT/CTvs.CC：OR＝2.26，95％CI（1.50，3.39），P＜0.001]的发生风险；MTHFRA1298C突变型显著降低了严重血液毒性[CC/ACvs.AA：OR＝0.17，95％CI（0.04，0.76），P＝0.02]的发生风险，具体包括降低了白细胞减少[CC/ACvs.AA：OR＝0.68，95％CI（0.48，0.97），P＝0.03；CCvs.AC/AA：OR＝0.28，95％CI（0.14，0.59），P＜0.001]、严重白细胞减少[CC/ACvs.AA：OR＝0.43，95％CI（0.19，0.97），P＝0.04]的发生风险。结论：在血液恶性肿瘤患者中，MTHFRC677T突变型可能增加HDMTX血液毒性发生风险，包括白细胞减少以及粒细胞减少；而MTHFRA1298C突变型则可能降低HDMTX血液毒性发生风险，包括白细胞减少。

Abstract

OBJECTIVE：To systematically evaluate the c orrelation of methylenetetra hydrofolate reductase （MTHFR）C677T and A 1298C gene polymorphisms with blood system adverse events induced by high-dose of methotrexate （HDMTX）. METHODS ： Retrieved from Medline ，Embase，Clinical Trials.gov ，CNKI，Wanfang database ，CBM，cohort studies about MTHFR gene polymorphism in hematological neoplasm treated by HDMTX were collected from inceptions to March 2018. After data extraction of included literatures ，quality evaluation with Newcastle Ottawa scale ，Meta-analysis was performed for adverse events of blood system induced by HDMTX in different genetic models with Rev Man 5.3 software. RESULTS ：Totally 25 cohort studies were included，23 studies of which were related to MTHFR C677T site （including 1 858 patients）and 16 studies related to MTHFR A1298C site （including 1 088 patients）. Results of Meta-analysis showed that MTHFR C677T mutation type significantly increased the risk of hematotoxicity [TT/CT vs. CC ：OR＝1.57，95％CI（1.12，2.20），P＝0.009；TT vs. CT/CC ：OR＝2.19，95％CI（1.49， 3.23），P＜0.001；T vs. C ：OR＝1.34，95％CI（1.03，1.74）， P＝0.03] and severe hematotoxicity [TT/CT vs. CC ：OR＝m 2.33，95％CI（1.43，3.81），P＜0.001]，including leukopenia [TT/CT vs. CC ：OR＝1.37，95％CI（1.02，1.82），P＝0.03]， severe leukopenia [TT/CT vs. CC ：OR＝1.63，95％CI（1.03， 010-82265810。E-mail：zhao_rongsheng@163.com 2.56），P＝0.04]，severe gra nulopenia [TT/CT vs. CC ：OR＝ ·2.26，95％CI（1.50，3.39），P＜0.001]. The mutation genotypes of MTHFR A1298C significantly decreased the risk of severe hematotoxicity [CC/AC vs. AA ：OR＝0.17，95％CI（0.04，0.76），P＝0.02]，including leukopenia [CC/AC vs. AA ：OR＝0.68， 95％CI（0.48，0.97），P＝0.03；CC vs. AC/AA ：OR＝0.28，95％CI（0.14，0.59），P＜0.001] and severe leukopenia [CC/AC vs. AA：OR＝0.43，95％CI（0.19，0.97），P＝0.04]. CONCLUSIONS ：Among patients with hematological neoplasms ，MTHFR C677T mutation may significantly increase the risk of hematotoxicity by HDMTX including the risk of leukopenia and granulopenia ；while MTHFR A1298C may reduce the risk of hematotoxicity by HDMTX ，including the risk of leukopenia.

关键词

亚甲基四氢叶酸还原酶基因多态性大剂量甲氨蝶呤血液恶性肿瘤安全性Meta分析

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

替吉奥联合化疗治疗中晚期非小细胞肺癌的疗效和安全性的Meta分析

10％葡萄糖酸钙注射液辅助预防剖宫产产后出血疗效的系统评价

香菇多糖注射液联合化疗治疗非小细胞肺癌的疗效与安全性的Meta分析

美罗培南治疗腹腔内感染的临床有效性及安全性评价

替米沙坦对比氯沙坦治疗原发性高血压的疗效与安全性的Meta分析

Related Author

余佳文王　增程　斌

陈宝妫张幼萍陈瑜

游如旭王凯平黄璞周洪波张玉

朱玲童荣生陈岷李晋奇

马卓司霞陈月冯婉玉

杨敏宁红饶友义

李玲宋夏胡汉昆杨梦歌刘萍刘薇芝黎明丽

杨兴缨高明太焦海胜肖吉元

Related Institution

Dept. of Rheumatology and Immunology， Hengshui Municipal People’s Hospital

College of Clinical Medicine， Hebei Medical University

Dept. of General Medicine， Hengshui Municipal People’s Hospital

Dept. of Pharmacy， Nanjing Drum Tower Hospital

School of Basic Medicine and Clinical Pharmacy， China Pharmaceutical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰